Market News How it works Learn FAQ
| RCT 0.0827 8.67% | NU 12.59 -16.95% | EWZ 34.15 -19.82% | BBD 2.93 -28.01% | TGL 0.2427 9.57% | AZTR 1.53 113.99% | ITUB 7.7 -20.37% | XP 15.705 -48.36% | NVD 3.99 -4.77% | SRTM 0.3 -30.28% | WFF 0.0898 12.25% | SPCX 146.9 -0.40% | PBR 22.5 -13.99% | SHFS 0.094 -29.00% | SOXL 90.5 8.31% | INTC 90.47 4.04% | VALE 12 -3.23% | NVDA 216 2.39% | CLRO 4.97 52.92% | NOK 8.64 6.14% | JBLU 2.37 -9.71% | TSLL 10.76 10.25% | CRWV 55.19 1.76% | GCDT 0.1545 -12.27% | SOXS 47.98 -8.54% | RIG 6.53 1.87% | NWGL 0.0869 5.98% | ABEV 2.83 -14.24% | RWM 14.5 -0.34% | BITO 10.65 -1.66% | AAL 12.2 0.74% | GPUS 0.1785 5.68% | TSLG 5.38 10.47% | T 20.85 -0.38% | SGRY 23.25 47.62% | IREN 25.43 2.11% | INTR 4.68 -34.91% | SBS 4.73 -26.09% | NFLX 63.9 -2.96% | GRAB 2.71 -2.87% | TSLA 391.62 5.21% | QID 14.22 -2.27% | WULF 11.98 5.83% | TQQQ 68.43 3.23% | CIFR 7.71 -2.90% | RBNE 0.17 -10.53% | SID 0.9118 -22.73% | SPDN 8.5 -0.47% | VZ 43.1 -3.49% | LUCD 0.5007 21.82%
SKSkye Bioscience, Inc. logo

Skye Bioscience, Inc. (SKYE)

NASDAQ · Currency in USD
$1.57 ▲ +0.03 (+1.95%)
At close: Oct 26, 4:00 PM ET. Market closed.
$1.57 ▲ +0.00 (+0.00%)
After hours: Oct 26, 7:30 PM ET

Summary

Previous Close
$1.54
Open
$1.50
Day's Range
$1.50 – $1.60
52 Week Range
$1.50 – $13.28
Volume
19,490
Avg. Volume
287,805
Market Cap
$6.95M
Beta (5Y Monthly)
2.86
PE Ratio (TTM)
--
EPS (TTM)
-$10.18
Earnings Date
Nov 9, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$12.00

Profile: Skye Bioscience, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
2
CEO
Punit Dhillon

Skye Bioscience, Inc., a clinical-stage biotechnology company, focuses on developing molecules that modulate G-protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021.

Earnings

Next report: Mon, Nov 9, 2026
EPS estimate -$1.14
DateEst.Actual
Aug 14, 2026-$2.04-$2.16Miss
May 11, 2026-$0.29-$0.32Miss
Mar 19, 2026-$2.32-$2.88Miss
Nov 10, 2025-$2.64-$2.56Beat
Aug 8, 2025-$2.72-$0.44Beat
May 8, 2025-$2.48-$0.28Beat

Analyst view

Consensus price target
$12.00 ▲ +664.3%
Range $2.00 – $21.00
Rating: Buy
Buy 100% · Hold 0% · Sell 0%

Get free alerts on SKYE and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.